Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study.
Yian LinAdam X MaihoferEmma StappMegan RitcheyNey Alliey-RodriguezAmit AnandYokesh BalaramanWade H BerrettiniHolli BertramAbesh BhattacharjeeCynthia V CalkinCarla ConroyWilliam H CoryellNicole D'ArcangeloAnna DeModenaJoanna M BiernackaCarrie FisherNicole FrazierMark FryeKeming GaoJulie GarnhamElliot GershonKara GlazerFernando S GoesToyomi GotoElizabeth KarbergGloria HarringtonPetter JakobsenMasoud KamaliMarisa KellySusan G LeckbandFalk W LohoffAndrea StautlandMichael J McCarthyMelvin G McInnisFrancis MondimoreGunnar MorkenMichael C NealeKetil J OedegaardVigdis Elin Giever SyrstadKelly RyanMartha SchinagleHelle SchoeyenOle A AndreassenMarth ShawPaul D ShillingClaire SlaneyBruce TarwaterJoseph R CalabreseMartin AldaCaroline M NievergeltPeter P ZandiJohn R KelsoePublished in: Bipolar disorders (2021)
In this PGBD Study of lithium response, several clinical features were found to be associated with failure to respond to lithium. Future validation is needed to confirm these clinical predictors of treatment failure and their use clinically to distinguish who will do well on lithium before starting pharmacotherapy.